Symbols / VTVT
VTVT Chart
About
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. The company was incorporated in 2015 and is headquartered in High Point, North Carolina.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 156.85M |
| Enterprise Value | 396.09M | Income | -23.47M | Sales | 17.00K |
| Book/sh | 5.68 | Cash/sh | 7.94 | Dividend Yield | — |
| Payout | 0.00% | Employees | 23 | IPO | — |
| P/E | — | Forward P/E | -10.00 | PEG | — |
| P/S | 9226.55 | P/B | 7.01 | P/C | — |
| EV/EBITDA | -13.30 | EV/Sales | 23299.54 | Quick Ratio | 9.69 |
| Current Ratio | 9.79 | Debt/Eq | 0.51 | LT Debt/Eq | — |
| EPS (ttm) | -3.30 | EPS next Y | -3.98 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-06 16:00 | ROA | -26.12% |
| ROE | -64.17% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -1753.82% | Profit Margin | 0.00% | Shs Outstand | 3.94M |
| Shs Float | 2.90M | Short Float | 1.30% | Short Ratio | 1.48 |
| Short Interest | — | 52W High | 44.00 | 52W Low | 14.00 |
| Beta | 0.46 | Avg Volume | 18.98K | Volume | 54.21K |
| Target Price | $51.20 | Recom | Strong_buy | Prev Close | $35.13 |
| Price | $39.83 | Change | 13.36% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$51.20
Mean price target
2. Current target
$39.83
Latest analyst target
3. DCF / Fair value
$-50.81
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$39.83
Low
$35.00
High
$67.00
Mean
$51.20
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-27 | main | BTIG | Buy → Buy | $49 |
| 2026-01-23 | init | Roth Capital | — → Buy | $58 |
| 2026-01-05 | init | TD Cowen | — → Buy | $67 |
| 2025-12-19 | main | HC Wainwright & Co. | Buy → Buy | $47 |
| 2025-11-19 | init | BTIG | — → Buy | $40 |
| 2025-08-13 | reit | HC Wainwright & Co. | Buy → Buy | $36 |
| 2025-04-09 | init | HC Wainwright & Co. | — → Buy | $36 |
| 2024-12-09 | init | Alliance Global Partners | — → Buy | $35 |
- vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat ue, 24 Feb 2026 10
- Type 1 diabetes drug developer vTv set for two investor conferences - Stock Titan Fri, 13 Feb 2026 08
- Behavioral Patterns of VTVT and Institutional Flows - Stock Traders Daily Wed, 18 Feb 2026 00
- Here's Why We're Not Too Worried About vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation - simplywall.st ue, 02 Dec 2025 08
- vTv Therapeutics (NASDAQ:VTVT) Shares Pass Above Fifty Day Moving Average - What's Next? - MarketBeat Fri, 20 Feb 2026 13
- All You Need to Know About vTv Therapeutics (VTVT) Rating Upgrade to Buy - Yahoo Finance ue, 11 Nov 2025 08
- vTv Therapeutics (VTVT) Price Target Increased by 16.19% to 48.20 - Nasdaq Wed, 14 Jan 2026 08
- Analysts Are Bullish on These Healthcare Stocks: vTv Therapeutics (VTVT), Acumen Pharmaceuticals (ABOS) - The Globe and Mail ue, 03 Feb 2026 08
- Roth/MKM initiates coverage on vTv Therapeutics stock with Buy rating - Investing.com Fri, 23 Jan 2026 08
- VTVT: TD Cowen Initiates Coverage with a Buy Rating and $67 Pric - GuruFocus Mon, 05 Jan 2026 08
- New Analyst Forecast: $VTVT Given $47 Price Target - Quiver Quantitative Fri, 19 Dec 2025 08
- Year-long trial will test a new pill to help people on insulin control diabetes - Stock Titan hu, 18 Dec 2025 08
- vTv Therapeutics (VTVT) Upgraded to Buy: Here's What You Should Know - Nasdaq Wed, 24 Dec 2025 08
- Roth Capital Initiates Coverage on VTVT with a 'Buy' Rating | VT - GuruFocus Fri, 23 Jan 2026 08
- vTv Therapeutics stock initiated with Buy rating at TD Cowen - Investing.com Mon, 05 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 106000 | 2349713 | — | Stock Award(Grant) at price 22.17 per share. | AKKARAJU SRINIVAS | Director | — | 2025-09-22 00:00:00 | I |
| 1 | 51000 | — | — | Stock Award(Grant) at price 0.00 per share. | BAKER BROS ADVISORS, L.P. | Unknown | — | 2025-09-03 00:00:00 | I |
| 2 | 224732 | 1910200 | — | Stock Award(Grant) at price 8.50 per share. | AKKARAJU SRINIVAS | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-02-27 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.00 | 0.21 | 0.27 |
| NormalizedEBITDA | -22.52M | -25.86M | -24.77M | -17.52M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -18.46M | -20.25M | -19.16M | -12.99M |
| ReconciledDepreciation | 89.00K | 90.00K | 92.00K | 89.00K |
| EBITDA | -22.52M | -25.86M | -24.77M | -17.52M |
| EBIT | -22.61M | -25.95M | -24.86M | -17.60M |
| NetInterestIncome | 1.56M | 459.00K | 337.00K | -11.00K |
| InterestExpense | 0.00 | 13.00K | 15.00K | 12.00K |
| InterestIncome | 1.56M | 472.00K | 352.00K | 1.00K |
| NormalizedIncome | -18.46M | -20.25M | -19.16M | -12.99M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -18.46M | -20.25M | -19.16M | -12.99M |
| TotalExpenses | 25.20M | 25.50M | 24.56M | 25.67M |
| TotalOperatingIncomeAsReported | -24.18M | -25.50M | -22.54M | -21.66M |
| DilutedAverageShares | 5.77M | 2.08M | 1.87M | 1.52M |
| BasicAverageShares | 5.77M | 2.08M | 1.87M | 1.52M |
| DilutedEPS | -3.20 | -9.71 | -10.40 | -8.40 |
| BasicEPS | -3.20 | -9.71 | -10.40 | -8.40 |
| DilutedNIAvailtoComStockholders | -18.46M | -20.25M | -19.16M | -12.99M |
| NetIncomeCommonStockholders | -18.46M | -20.25M | -19.16M | -12.99M |
| NetIncome | -18.46M | -20.25M | -19.16M | -12.99M |
| MinorityInterests | 4.24M | 5.72M | 5.91M | 4.74M |
| NetIncomeIncludingNoncontrollingInterests | -22.70M | -25.97M | -25.07M | -17.73M |
| NetIncomeContinuousOperations | -22.70M | -25.97M | -25.07M | -17.73M |
| TaxProvision | 100.00K | 0.00 | 200.00K | 115.00K |
| PretaxIncome | -22.61M | -25.97M | -24.87M | -17.62M |
| OtherIncomeExpense | 10.00K | -923.00K | -2.67M | 4.06M |
| OtherNonOperatingIncomeExpenses | 10.00K | -923.00K | -2.67M | 4.06M |
| NetNonOperatingInterestIncomeExpense | 1.56M | 459.00K | 337.00K | -11.00K |
| InterestExpenseNonOperating | 0.00 | 13.00K | 15.00K | 12.00K |
| InterestIncomeNonOperating | 1.56M | 472.00K | 352.00K | 1.00K |
| OperatingIncome | -24.18M | -25.50M | -22.54M | -21.66M |
| OperatingExpense | 25.20M | 25.50M | 24.56M | 25.67M |
| ResearchAndDevelopment | 11.55M | 13.60M | 12.36M | 13.32M |
| SellingGeneralAndAdministration | 13.65M | 11.91M | 12.20M | 12.34M |
| GeneralAndAdministrativeExpense | 13.65M | 11.91M | 12.20M | 12.34M |
| OtherGandA | 13.65M | 11.91M | 12.20M | 12.34M |
| TotalRevenue | 1.02M | 0.00 | 2.02M | 4.00M |
| OperatingRevenue | 1.02M | 0.00 | 2.02M | 4.00M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 2.61M | 2.08M | 2.04M | 1.67M |
| ShareIssued | 2.61M | 2.08M | 2.04M | 1.67M |
| TotalDebt | 169.00K | 529.00K | 716.00K | 932.00K |
| TangibleBookValue | 12.20M | -24.68M | -10.74M | -9.74M |
| InvestedCapital | 12.20M | -24.49M | -10.52M | -9.48M |
| WorkingCapital | 32.92M | 38.00K | 19.39M | 7.12M |
| NetTangibleAssets | 12.20M | -24.68M | -10.74M | -9.74M |
| CapitalLeaseObligations | 169.00K | 338.00K | 492.00K | 676.00K |
| CommonStockEquity | 12.20M | -24.68M | -10.74M | -9.74M |
| TotalCapitalization | 12.20M | -24.68M | -10.74M | -9.74M |
| TotalEquityGrossMinorityInterest | 14.30M | -18.55M | 5.84M | 15.22M |
| MinorityInterest | 2.10M | 6.13M | 16.58M | 24.96M |
| StockholdersEquity | 12.20M | -24.68M | -10.74M | -9.74M |
| RetainedEarnings | -299.72M | -281.04M | -265.52M | -248.83M |
| AdditionalPaidInCapital | 311.88M | 256.33M | 254.76M | 238.19M |
| CapitalStock | 32.00K | 27.00K | 27.00K | 901.00K |
| CommonStock | 32.00K | 27.00K | 27.00K | 901.00K |
| TotalLiabilitiesNetMinorityInterest | 23.96M | 29.57M | 27.40M | 10.25M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 18.77M | 18.95M | 19.69M | 1.75M |
| PreferredSecuritiesOutsideStockEquity | 16.58M | 24.96M | ||
| DerivativeProductLiabilities | 100.00K | 110.00K | 684.00K | 1.26M |
| NonCurrentDeferredLiabilities | 18.67M | 18.67M | 18.67M | 0.00 |
| NonCurrentDeferredRevenue | 18.67M | 18.67M | 18.67M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 169.00K | 338.00K | 492.00K |
| LongTermCapitalLeaseObligation | 0.00 | 169.00K | 338.00K | 492.00K |
| CurrentLiabilities | 5.20M | 10.62M | 7.71M | 8.50M |
| CurrentDeferredLiabilities | 0.00 | 17.00K | 17.00K | 35.00K |
| CurrentDeferredRevenue | 0.00 | 17.00K | 17.00K | 35.00K |
| CurrentDebtAndCapitalLeaseObligation | 169.00K | 360.00K | 378.00K | 440.00K |
| CurrentCapitalLeaseObligation | 169.00K | 169.00K | 154.00K | 184.00K |
| CurrentDebt | 191.00K | 224.00K | 256.00K | |
| OtherCurrentBorrowings | 191.00K | 224.00K | 256.00K | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.51M | 1.47M | 788.00K | 3.20M |
| PayablesAndAccruedExpenses | 3.52M | 8.78M | 6.53M | 4.82M |
| CurrentAccruedExpenses | 2.58M | 4.70M | 4.06M | 2.94M |
| Payables | 939.00K | 4.08M | 2.46M | 1.88M |
| AccountsPayable | 939.00K | 4.08M | 2.46M | 1.88M |
| TotalAssets | 38.27M | 11.02M | 33.24M | 25.47M |
| TotalNonCurrentAssets | 153.00K | 361.00K | 6.14M | 9.85M |
| InvestmentsAndAdvances | 0.00 | 5.59M | 9.17M | |
| LongTermEquityInvestment | 0.00 | 5.59M | 9.17M | |
| NetPPE | 153.00K | 361.00K | 556.00K | 680.00K |
| AccumulatedDepreciation | -508.00K | -487.00K | -397.00K | -305.00K |
| GrossPPE | 661.00K | 848.00K | 953.00K | 985.00K |
| Leases | 406.00K | 406.00K | 406.00K | 406.00K |
| OtherProperties | 125.00K | 244.00K | 349.00K | 402.00K |
| MachineryFurnitureEquipment | 130.00K | 198.00K | 198.00K | 177.00K |
| BuildingsAndImprovements | 244.00K | 349.00K | 402.00K | |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 38.11M | 10.66M | 27.09M | 15.62M |
| CurrentDeferredAssets | 0.00 | 135.00K | ||
| PrepaidAssets | 1.30M | 1.11M | 2.55M | 2.01M |
| Receivables | 62.00K | 102.00K | 12.42M | 57.00K |
| NotesReceivable | 0.00 | 12.24M | 0.00 | |
| AccountsReceivable | 62.00K | 102.00K | 173.00K | 57.00K |
| CashCashEquivalentsAndShortTermInvestments | 36.75M | 9.45M | 12.13M | 13.41M |
| CashAndCashEquivalents | 36.75M | 9.45M | 12.13M | 13.41M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -25.31M | -19.08M | -16.04M | -19.31M |
| RepaymentOfDebt | -191.00K | -599.00K | -808.00K | -715.00K |
| IssuanceOfDebt | 0.00 | 566.00K | 776.00K | 887.00K |
| IssuanceOfCapitalStock | 52.80M | 12.03M | 14.79M | 26.76M |
| CapitalExpenditure | -21.00K | |||
| InterestPaidSupplementalData | 2.00K | 14.00K | 15.00K | 11.00K |
| IncomeTaxPaidSupplementalData | 100.00K | 0.00 | 200.00K | 115.00K |
| EndCashPosition | 36.75M | 9.45M | 12.13M | 13.41M |
| BeginningCashPosition | 9.45M | 12.13M | 13.41M | 5.75M |
| ChangesInCash | 27.30M | -2.68M | -1.29M | 7.67M |
| FinancingCashFlow | 52.61M | 12.00M | 14.75M | 26.98M |
| CashFlowFromContinuingFinancingActivities | 52.61M | 12.00M | 14.75M | 26.98M |
| ProceedsFromStockOptionExercised | 0.00 | 9.75M | 47.00K | |
| NetCommonStockIssuance | 52.80M | 12.03M | 14.79M | 26.76M |
| CommonStockIssuance | 52.80M | 12.03M | 14.79M | 26.76M |
| NetIssuancePaymentsOfDebt | -191.00K | -33.00K | -32.00K | 172.00K |
| NetShortTermDebtIssuance | -191.00K | -599.00K | -808.00K | -715.00K |
| ShortTermDebtPayments | -191.00K | -599.00K | -808.00K | -715.00K |
| NetLongTermDebtIssuance | 0.00 | 566.00K | 776.00K | 887.00K |
| LongTermDebtPayments | -599.00K | -808.00K | -715.00K | |
| LongTermDebtIssuance | 0.00 | 566.00K | 776.00K | 887.00K |
| InvestingCashFlow | 0.00 | 4.40M | -21.00K | 0.00 |
| CashFlowFromContinuingInvestingActivities | 0.00 | 4.40M | -21.00K | 0.00 |
| NetBusinessPurchaseAndSale | 0.00 | 4.40M | 0.00 | 0.00 |
| SaleOfBusiness | 0.00 | 4.40M | 0.00 | 0.00 |
| NetPPEPurchaseAndSale | 0.00 | 0.00 | -21.00K | 0.00 |
| PurchaseOfPPE | 0.00 | 0.00 | -21.00K | 0.00 |
| OperatingCashFlow | -25.31M | -19.08M | -16.02M | -19.31M |
| CashFlowFromContinuingOperatingActivities | -25.31M | -19.08M | -16.02M | -19.31M |
| ChangeInWorkingCapital | -5.44M | 4.39M | 5.38M | 35.00K |
| ChangeInOtherWorkingCapital | -17.00K | 6.76M | -1.00M | |
| ChangeInOtherCurrentLiabilities | -169.00K | -154.00K | 0.00 | -50.00K |
| ChangeInOtherCurrentAssets | 119.00K | 105.00K | 0.00 | 0.00 |
| ChangeInPayablesAndAccruedExpense | -5.21M | 2.93M | -856.00K | 1.83M |
| ChangeInAccruedExpense | 0.00 | 0.00 | ||
| ChangeInInterestPayable | 0.00 | 0.00 | ||
| ChangeInPayable | -856.00K | 1.83M | ||
| ChangeInAccountPayable | -856.00K | 1.83M | ||
| ChangeInPrepaidAssets | -196.00K | 1.44M | -403.00K | -839.00K |
| ChangeInReceivables | 40.00K | 71.00K | -116.00K | 101.00K |
| ChangesInAccountReceivables | 40.00K | 71.00K | -116.00K | 101.00K |
| OtherNonCashItems | 213.00K | -337.00K | ||
| StockBasedCompensation | 2.76M | 1.58M | 1.27M | 2.36M |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | 0.00 | 3.58M | -2.45M |
| AssetImpairmentCharge | 0.00 | 4.25M | 0.00 | 0.00 |
| DepreciationAmortizationDepletion | 89.00K | 90.00K | 92.00K | 89.00K |
| DepreciationAndAmortization | 89.00K | 90.00K | 92.00K | 89.00K |
| Depreciation | 89.00K | 90.00K | 92.00K | 89.00K |
| OperatingGainsLosses | -10.00K | -3.63M | -946.00K | -1.61M |
| GainLossOnInvestmentSecurities | -10.00K | -574.00K | -946.00K | -1.61M |
| GainLossOnSaleOfPPE | 0.00 | |||
| GainLossOnSaleOfBusiness | 0.00 | -3.06M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -22.70M | -25.97M | -25.07M | -17.73M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for VTVT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|